

# Micaela Morelli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7369532/micaela-morelli-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

160

papers

6,538

citations

42

h-index

76

g-index

162

ext. papers

7,108

ext. citations

5.1

avg, IF

5.59

L-index

#	Paper	IF	Citations
160	Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists <b>2021</b> , 1-24		
159	Involvement of the Protein Ras Homolog Enriched in the Striatum, Rhes, in Dopaminergic Neurons' Degeneration: Link to Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
158	Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2021</b> , 108, 118181	5.5	3
157	Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel. <i>European Journal of Neurology</i> , <b>2021</b> , 28, 1198-1209	6	6
156	In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice. <i>NeuroToxicology</i> , <b>2021</b> , 83, 1-13	4.4	2
155	Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes. <i>Biomolecules</i> , <b>2021</b> , 11,	5.9	10
154	Brief history of the medical and non-medical use of amphetamine-like psychostimulants. <i>Experimental Neurology</i> , <b>2021</b> , 342, 113754	5.7	2
153	Activation of Antioxidant and Proteolytic Pathways in the Nigrostriatal Dopaminergic System After 3,4-Methylenedioxymethamphetamine Administration: Sex-Related Differences. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 713486	5.6	1
152	Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT receptor agonist and A receptor antagonist. <i>Neuropharmacology</i> , <b>2021</b> , 181, 108183	5.5	2
151	Pharmacological interactions between adenosine A receptor antagonists and different neurotransmitter systems. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 80 Suppl 1, S37-S44	3.6	2
150	Gender Differences in Neurodegeneration, Neuroinflammation and Na-Ca Exchangers in the Female A53T Transgenic Mouse Model of Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , <b>2020</b> , 12, 118	5.3	6
149	Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2020</b> , 97, 109797	5.5	6
148	Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: A pilot study. <i>International Journal of Biological Macromolecules</i> , <b>2020</b> , 165, 665-674	7.9	12
147	Lack of Rhes Increases MDMA-Induced Neuroinflammation and Dopamine Neuron Degeneration: Role of Gender and Age. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	13
146	Odor Identification Performance in Idiopathic Parkinson's Disease Is Associated With Gender and the Genetic Variability of the Olfactory Binding Protein. <i>Chemical Senses</i> , <b>2019</b> , 44, 311-318	4.8	17
145	Fos expression induced by olanzapine and risperidone in the central extended amygdala. <i>European Journal of Pharmacology</i> , <b>2019</b> , 865, 172764	5.3	0
144	Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity. <i>Neurotoxicity Research</i> , <b>2018</b> , 34, 763-768	4.3	9

143	Role of adenosine A receptors in motor control: relevance to Parkinson's disease and dyskinesia. <i>Journal of Neural Transmission</i> , <b>2018</b> , 125, 1273-1286	4.3	23
142	6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson's disease. <i>Movement Disorders</i> , <b>2018</b> , 33, 1331-1339	7	13
141	Rhes Counteracts Dopamine Neuron Degeneration and Neuroinflammation Depending on Gender and Age. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 163	5.3	6
140	Neurochemical and Neurotoxic Effects of MDMA (Ecstasy) and Caffeine After Chronic Combined Administration in Mice. <i>Neurotoxicity Research</i> , <b>2018</b> , 33, 532-548	4.3	15
139	Modulation of Rat 50-kHz Ultrasonic Vocalizations by Glucocorticoid Signaling: Possible Relevance to Reward and Motivation. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 73-83	5.8	17
138	NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 725	9.8	19
137	Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. <i>Progress in Neurobiology</i> , <b>2017</b> , 155, 149-170	10.9	135
136	Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage. <i>Neurotoxicity Research</i> , <b>2017</b> , 32, 563-574	4.3	19
135	A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease. <i>European Journal of Pharmacology</i> , <b>2017</b> , 813, 10-16	5.3	14
134	Control of Motor Function by Adenosine A <sub>2A</sub> Receptors in Parkinson's and Huntington's Disease <b>2017</b> , 187-213		
133	Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181677	3.7	12
132	Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain. <i>NeuroToxicology</i> , <b>2016</b> , 56, 127-138	4.4	13
131	Antidyskinetic effect of A <sub>2A</sub> and 5HT <sub>1A/1B</sub> receptor ligands in two animal models of Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 501-11	7	30
130	The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging. <i>Movement Disorders</i> , <b>2016</b> , 31, 583-9	7	10
129	Activation of adenosine A <sub>2A</sub> receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation. <i>Psychopharmacology</i> , <b>2016</b> , 233, 507-19	4.7	22
128	Metformin Prevented Dopaminergic Neurotoxicity Induced by 3,4-Methylenedioxymethamphetamine Administration. <i>Neurotoxicity Research</i> , <b>2016</b> , 30, 101-9	4.3	19
127	Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease. <i>Molecular Neurodegeneration</i> , <b>2016</b> , 11, 6	19	41
126	Methylxanthines and Drug Dependence: Interactions and Toxicity <b>2016</b> , 912-923		1

125	Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent. <i>Journal of Neurochemistry</i> , <b>2016</b> , 136, 148-62	6	21
124	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , <b>2015</b> , 132, 96-168	10.9	282
123	Repeated amphetamine administration and long-term effects on 50-kHz ultrasonic vocalizations: possible relevance to the motivational and dopamine-stimulating properties of the drug. <i>European Neuropsychopharmacology</i> , <b>2015</b> , 25, 343-55	1.2	34
122	Involvement of Glutamate NMDA Receptors in the Acute, Long-Term, and Conditioned Effects of Amphetamine on Rat 50 kHz Ultrasonic Vocalizations. <i>International Journal of Neuropsychopharmacology</i> , <b>2015</b> , 18, pyv057	5.8	28
121	Adenosine A2A Receptor Antagonists in L-DOPA-Induced Motor Fluctuations. <i>Current Topics in Neurotoxicity</i> , <b>2015</b> , 163-182		1
120	MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. <i>Psychopharmacology</i> , <b>2014</b> , 231, 4007-18	4.7	35
119	Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. <i>Journal of Neurochemistry</i> , <b>2014</b> , 130, 472-89	6	44
118	Antagonism of Adenosine A1 or A2A Receptors Amplifies the Effects of MDMA on Glial Activation in the Mouse Brain: Relevance to Caffeine/MDMA Interactions. <i>Journal of Caffeine Research</i> , <b>2014</b> , 4, 41-47		2
117	Direct and long-lasting effects elicited by repeated drug administration on 50-kHz ultrasonic vocalizations are regulated differently: implications for the study of the affective properties of drugs of abuse. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 429-41	5.8	49
116	Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?. <i>Journal of Neurochemistry</i> , <b>2014</b> , 131, 284-9	6	9
115	A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. <i>Neurotoxicity Research</i> , <b>2014</b> , 25, 392-401	4.3	21
114	Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists <b>2014</b> , 2281-2298		0
113	Contribution of Caffeine to the Psychostimulant, Neuroinflammatory and Neurotoxic Effects of Amphetamine-Related Drugs. <i>Journal of Caffeine Research</i> , <b>2013</b> , 3, 79-84		6
112	Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. <i>Experimental Neurology</i> , <b>2013</b> , 247, 663-72	5.7	16
111	Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. <i>Journal of Neurochemistry</i> , <b>2013</b> , 124, 69-78	6	35
110	MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. <i>Movement Disorders</i> , <b>2013</b> , 28, 1957-65	7	39
109	Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. <i>Frontiers in Computational Neuroscience</i> , <b>2013</b> , 7, 142	3.5	4
108	Symptomatic and Neuroprotective Effects of A2A Receptor Antagonists in Parkinson's Disease <b>2013</b> , 361-384		3

107	Late-onset Parkinsonism in NFB/c-Rel-deficient mice. <i>Brain</i> , <b>2012</b> , 135, 2750-65	11.2	55
106	Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective?. <i>Experimental Neurology</i> , <b>2012</b> , 237, 218-22	5.7	6
105	Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward. <i>Neuropharmacology</i> , <b>2012</b> , 63, 224-34	5.5	80
104	A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. <i>Parkinson's Disease</i> , <b>2012</b> , 2012, 4898-53	5.3	13
103	Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. <i>Parkinson's Disease</i> , <b>2012</b> , 2012, 910454	2.6	9
102	Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. <i>NeuroRehabilitation</i> , <b>2012</b> , 30, 295-301	2	15
101	Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. <i>Psychoneuroendocrinology</i> , <b>2011</b> , 36, 463-72 <sup>5</sup>	5	34
100	Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. <i>Neurotoxicity Research</i> , <b>2011</b> , 19, 603-27	4.3	41
99	Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. <i>Neurotoxicity Research</i> , <b>2011</b> , 20, 170-81	4.3	12
98	Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. <i>EPMA Journal</i> , <b>2011</b> , 2, 197-210	8.8	39
97	Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. <i>Synapse</i> , <b>2011</b> , 65, 181-8	2.4	20
96	What Do You See as the Main Priorities, Opportunities, and Challenges in Caffeine Research in the Next Five Years?. <i>Journal of Caffeine Research</i> , <b>2011</b> , 1, 5-12		3
95	Methylxanthines and drug dependence: a focus on interactions with substances of abuse. <i>Handbook of Experimental Pharmacology</i> , <b>2011</b> , 483-507	3.2	18
94	Role of Adenosine in the Basal Ganglia. <i>Handbook of Behavioral Neuroscience</i> , <b>2010</b> , 201-217	0.7	
93	Pathophysiological roles for purines: adenosine, caffeine and urate. <i>Progress in Brain Research</i> , <b>2010</b> , 183, 183-208	2.9	65
92	A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. <i>Neuropharmacology</i> , <b>2010</b> , 58, 613-23	5.5	38
91	Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. <i>Experimental Neurology</i> , <b>2010</b> , 224, 395-402	5.7	15
90	Can dietary substances protect against Parkinson's disease? The case of caffeine. <i>Experimental Neurology</i> , <b>2010</b> , 225, 246-9	5.7	2

89	Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. <i>Experimental Brain Research</i> , <b>2010</b> , 202, 1-14	2.3	37
88	Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. <i>Neurotoxicity Research</i> , <b>2010</b> , 17, 435-43	4.3	41
87	Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. <i>EPMA Journal</i> , <b>2010</b> , 1, 273-92	8.8	23
86	Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. <i>Neurotoxicity Research</i> , <b>2009</b> , 15, 111-22	4.3	57
85	Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. <i>Journal of Neurochemistry</i> , <b>2009</b> , 111, 1478-89	6	57
84	Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. <i>Neurotherapeutics</i> , <b>2009</b> , 6, 128-40	6.4	19
83	Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction. <i>Neuroscience</i> , <b>2009</b> , 158, 1625-31	3.9	12
82	Adenosine A2A receptors and Parkinson's disease. <i>Handbook of Experimental Pharmacology</i> , <b>2009</b> , 589-615	3.5	88
81	Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. <i>Behavioural Pharmacology</i> , <b>2009</b> , 20, 363-79	2.4	48
80	Behavioural Correlates of Dopaminergic Agonists Dyskinetic Potential in the 6-OHDA-Lesioned Rat. <i>Advances in Behavioral Biology</i> , <b>2009</b> , 461-470		
79	Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. <i>Journal of Medicinal Chemistry</i> , <b>2008</b> , 51, 5798-806	8.3	70
78	Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinesic drugs: behavioural and biochemical evidence. <i>Parkinsonism and Related Disorders</i> , <b>2008</b> , 14 Suppl 2, S165-8	3.6	15
77	Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. <i>Experimental Brain Research</i> , <b>2008</b> , 185, 595-601	2.3	40
76	Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists. <i>Synapse</i> , <b>2008</b> , 62, 345-51	2.4	10
75	Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects. <i>Synapse</i> , <b>2008</b> , 62, 394-7	2.4	22
74	Behavioral and biochemical correlates of the dyskinesic potential of dopaminergic agonists in the 6-OHDA lesioned rat. <i>Synapse</i> , <b>2008</b> , 62, 524-33	2.4	38
73	Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. <i>Synapse</i> , <b>2007</b> , 61, 606-14	2.4	68
72	Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. <i>European Journal of Pharmacology</i> , <b>2007</b> , 566, 94-102	5.3	68



71	The 6-hydroxydopamine model of Parkinson's disease. <i>Neurotoxicity Research</i> , <b>2007</b> , 11, 151-67	4.3	249
70	Role of adenosine A2A receptors in parkinsonian motor impairment and L-DOPA-induced motor complications. <i>Progress in Neurobiology</i> , <b>2007</b> , 83, 293-309	10.9	123
69	Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. <i>Journal of the Neurological Sciences</i> , <b>2006</b> , 248, 48-52	3.2	24
68	Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists. <i>Experimental Neurology</i> , <b>2006</b> , 202, 255-7	5.7	17
67	Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. <i>Behavioural Brain Research</i> , <b>2006</b> , 171, 175-8	3.4	36
66	Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. <i>Behavioural Brain Research</i> , <b>2006</b> , 172, 72-9	3.4	29
65	Targeting adenosine A2A receptors in Parkinson's disease. <i>Trends in Neurosciences</i> , <b>2006</b> , 29, 647-54	13.3	364
64	How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?. <i>Behavioural Pharmacology</i> , <b>2006</b> , 17, 393-402	2.4	22
63	Potential of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. <i>Journal of Neurochemistry</i> , <b>2006</b> , 98, 1078-89	6	21
62	New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. <i>Life Sciences</i> , <b>2005</b> , 77, 3259-67	6.8	72
61	Chapter I The organization and circuits of mesencephalic dopaminergic neurons and the distribution of dopamine receptors in the brain. <i>Handbook of Chemical Neuroanatomy</i> , <b>2005</b> , 1-107		36
60	Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists. <i>Behavioural Pharmacology</i> , <b>2005</b> , 16, 621-6	2.4	6
59	New adenosine A2A receptor antagonists: actions on Parkinson's disease models. <i>European Journal of Pharmacology</i> , <b>2005</b> , 512, 157-64	5.3	37
58	Changes in the Expression of Tonic and Phasic Neurochemical Markers of Activity in a Rat Model of L-DOPA Induced Dyskinesia <b>2005</b> , 371-378		
57	Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. <i>Neuropsychopharmacology</i> , <b>2004</b> , 29, 1597-609	8.7	42
56	Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. <i>Bioorganic and Medicinal Chemistry</i> , <b>2004</b> , 12, 4169-77	3.4	25
55	Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. <i>Experimental Neurology</i> , <b>2004</b> , 189, 182-8	5.7	67
54	Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. <i>Neuropsychopharmacology</i> , <b>2003</b> , 28, 1752-9	8.7	42

53	EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. <i>Brain Research</i> , <b>2003</b> , 972, 177-85	3.7	21
52	Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. <i>European Journal of Pharmacology</i> , <b>2003</b> , 464, 33-8	5.3	42
51	Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. <i>European Journal of Medicinal Chemistry</i> , <b>2003</b> , 38, 513-8	6.8	53
50	Blockade of A2A receptors plus L-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from L-DOPA alone in the rat globus pallidus and substantia nigra reticulata. <i>Experimental Neurology</i> , <b>2003</b> , 184, 679-87	5.7	22
49	Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease. <i>Experimental Neurology</i> , <b>2003</b> , 184, 20-3	5.7	16
48	Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. <i>Neurology</i> , <b>2003</b> , 61, S39-43	6.5	17
47	Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. <i>European Journal of Pharmacology</i> , <b>2002</b> , 446, 75-82	5.3	63
46	Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. <i>Psychopharmacology</i> , <b>2002</b> , 162, 246-54	4.7	24
45	Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. <i>Synapse</i> , <b>2002</b> , 44, 166-74	2.4	57
44	Different Patterns of Behavior and Gene Expression Induced by Chronic L-Dopa and A2A Antagonists Plus L-Dopa Treatments in 6-Hydroxydopamine Lesioned Rats. <i>Advances in Behavioral Biology</i> , <b>2002</b> , 19-28		
43	Modulation by adenosine A2A receptors of dopamine-mediated motor behavior as a basis for antiparkinsonian disease drugs. <i>Drug Development Research</i> , <b>2001</b> , 52, 387-393	5.1	2
42	Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. <i>Synapse</i> , <b>2001</b> , 39, 233-238	2.4	92
41	Cross-sensitization between the motor activating effects of bromocriptine and caffeine: role of adenosine A(2A) receptors. <i>Behavioural Brain Research</i> , <b>2000</b> , 114, 97-105	3.4	23
40	Involvement of adenosine A2A receptors in the induction of c-fos expression by clozapine and haloperidol. <i>Neuropsychopharmacology</i> , <b>1999</b> , 20, 44-51	8.7	51
39	Differential induction of Fos-like-immunoreactivity in the extended amygdala after haloperidol and clozapine. <i>Neuropsychopharmacology</i> , <b>1999</b> , 21, 93-100	8.7	16
38	Induction of Fos-like-immunoreactivity in the central extended amygdala by antidepressant drugs. <i>Synapse</i> , <b>1999</b> , 31, 1-4	2.4	38
37	Role of dopamine receptors in the induction and expression of rotational behavior induced by caffeine in 6-hydroxydopamine-lesioned rats. <i>Drug Development Research</i> , <b>1998</b> , 45, 373-378	5.1	4
36	Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. <i>European Journal of Pharmacology</i> , <b>1997</b> , 321, 143-7	5.3	130



35	Priming of 6-hydroxydopamine-lesioned rats with L-DOPA or quinpirole results in an increase in dopamine D1 receptor-dependent cyclic AMP production in striatal tissue. <i>European Journal of Pharmacology</i> , <b>1997</b> , 331, 23-6	5.3	21
34	Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. <i>Trends in Neurosciences</i> , <b>1997</b> , 20, 482-7	13.3	676
33	Behavioural sensitization in 6-hydroxydopamine-lesioned rats is related to compositional changes of the AP-1 transcription factor: evidence for induction of FosB- and JunD-related proteins. <i>Molecular Brain Research</i> , <b>1997</b> , 52, 307-17		29
32	Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas. <i>Brain Research</i> , <b>1997</b> , 759, 41-9	3.7	58
31	Neuropharmacology of the adenosine A2A receptors. <i>Drug Development Research</i> , <b>1996</b> , 39, 450-460	5.1	20
30	C-Fos expression as a molecular marker in corticotropin-releasing factor-induced seizures. <i>Synapse</i> , <b>1996</b> , 24, 297-304	2.4	5
29	Differential effect of MK 801 and scopolamine on c-fos expression induced by L-dopa in the striatum of 6-hydroxydopamine lesioned rats. <i>Synapse</i> , <b>1994</b> , 18, 288-93	2.4	27
28	Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. <i>European Journal of Pharmacology</i> , <b>1994</b> , 251, 21-5	5.3	85
27	Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. <i>Trends in Neurosciences</i> , <b>1994</b> , 17, 228-33	13.3	417
26	Acetylcholine, Dopamine and NMDA Transmission in the Caudate-Putamen: Their Interaction and Function as a Striatal Modulatory System. <i>Advances in Behavioral Biology</i> , <b>1994</b> , 491-505		3
25	L-dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors. <i>Brain Research</i> , <b>1993</b> , 623, 334-6	3.7	49
24	Local cerebral glucose utilization after D1 receptor stimulation in 6-OHDA lesioned rats: effect of sensitization (priming) with a dopaminergic agonist. <i>Synapse</i> , <b>1993</b> , 13, 264-9	2.4	29
23	Expression of c-fos protein in the experimental epilepsy induced by pilocarpine. <i>Synapse</i> , <b>1993</b> , 14, 1-9	2.4	52
22	Priming as a Model of Behavioural Sensitization. <i>Developmental Pharmacology and Therapeutics</i> , <b>1992</b> , 18, 223-227		19
21	Metabolic mapping of the synergism between MK-801 and SKF 38393 in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. <i>Synapse</i> , <b>1992</b> , 12, 255-60	2.4	10
20	Priming of the Behavioral Expression of Dopamine-Receptor Supersensitivity in the Basal Ganglia: Pharmacological and Biochemical Studies. <i>Advances in Behavioral Biology</i> , <b>1991</b> , 443-452		
19	MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease. <i>European Journal of Pharmacology</i> , <b>1990</b> , 182, 611-2	5.3	93
18	Changes in the D1 receptor-adenylate cyclase complex after priming. <i>European Journal of Pharmacology</i> , <b>1990</b> , 180, 365-7	5.3	23

17	The Influence of Priming on the Behavioral Expression of Dopamine Receptor Supersensitivity in Basal Ganglia. <i>Advances in Behavioral Biology</i> , <b>1990</b> , 579-584		
16	Substantia nigra as a site of origin of dopamine-dependent motor syndromes induced by stimulation of mu and delta opioid receptors. <i>Brain Research</i> , <b>1989</b> , 487, 120-30	3-7	46
15	Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. <i>European Journal of Pharmacology</i> , <b>1989</b> , 162, 329-35	5-3	81
14	Priming of the expression of dopamine D-1 receptor supersensitivity: Behavioral and neurochemical studies. <i>Pharmacological Research Communications</i> , <b>1988</b> , 20, 255		
13	Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turning. <i>European Journal of Pharmacology</i> , <b>1987</b> , 141, 101-7	5-3	78
12	6-Hydroxydopamine lesions reduce specific [ <sup>3</sup> H]sulpiride binding in the rat substantia nigra: direct evidence for the existence of nigral D-2 autoreceptors. <i>European Journal of Pharmacology</i> , <b>1987</b> , 140, 99-104	5-3	22
11	Behavioural expression of D-1 receptor supersensitivity depends on previous stimulation of D-2 receptors. <i>Life Sciences</i> , <b>1987</b> , 40, 245-51	6.8	39
10	Catalepsy induced by SCH 23390 in rats. <i>European Journal of Pharmacology</i> , <b>1985</b> , 117, 179-85	5-3	119
9	Output Pathways Mediating Basal Ganglia Function. <i>Advances in Behavioral Biology</i> , <b>1984</b> , 443-466		6
8	[ <sup>3</sup> H]Ro5-4864 benzodiazepine binding in the kainate lesioned striatum and Huntington's diseased basal ganglia. <i>Brain Research</i> , <b>1982</b> , 248, 396-401	3-7	150
7	The effect of GABA on in vitro binding of two novel non-benzodiazepines, PK 8165 and CGS 8216, to benzodiazepine receptors in the rat brain. <i>Life Sciences</i> , <b>1982</b> , 31, 77-81	6.8	14
6	The effect of temperature on CL 218872 and propyl beta-carboline-3-carboxylate inhibition of [ <sup>3</sup> H]-flunitrazepam binding in rat brain. <i>Biochemical and Biophysical Research Communications</i> , <b>1982</b> , 105, 1532-7	3-4	21
5	[ <sup>3</sup> H]CL 218,872, a novel triazolopyridazine which labels the benzodiazepine receptors in rat brain. <i>European Journal of Pharmacology</i> , <b>1982</b> , 77, 351-4	5-3	35
4	Benzodiazepine receptor binding in young, mature and senescent rat brain and kidney. <i>Neurobiology of Aging</i> , <b>1981</b> , 2, 83-8	5.6	60
3	Irreversible neuronal damage after intrastriatal injection of colchicine. <i>Pharmacological Research Communications</i> , <b>1980</b> , 12, 719-23		1
2	Lesions of substantia nigra by kainic acid: effects on apomorphine-induced stereotyped behaviour. <i>Brain Research</i> , <b>1980</b> , 191, 67-78	3-7	44
1	Loss of striatal neurons after local microinjection of colchicine. <i>Neuroscience Letters</i> , <b>1980</b> , 16, 131-5	3-3	12